Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study

Archive ouverte

Houvenaeghel, Gilles | Nonneville, Alexandre, De | Cohen, Monique | Classe, Jean-Marc | Reyal, Fabien | Mazouni, Chafika | Faure, Christelle | Martinez, Alejandra | Chauvet, Marie-Pierre | Darai, Emile | Coutant, Charles | Colombo, Pierre-Emmanuel | Gimbergues, Pierre | Azuar, Anne-Sophie | Rouzier, Roman | Lara, Christine Tunon, De | Crochet, Patrice | Rua, Sandrine | Goncalves, Anthony

Edité par CCSD ; Elsevier -

International audience. Introduction: Few data have been reported regarding endocrine therapy (ET) in patients with small pT1a-b ER-postive breast cancer (BC). Thus, we conducted a study to detect possible survival improvements due to ET in such patients. Methods: Our retrospective observational study included 5545 patients with pT1a-b ERpositive BC treated in 15 French centres, excluding patients with HER2-positive status, neoadjuvant chemotherapy, ER-negative status, unknown pN status or in situ BC. We estimated disease-free survival (DFS), recurrence-free survival (RFS) and overall survival (OS) via univariate analysis and multivariate Cox regression. Results: Most patients (80.3%: 4453) received ET and-when compared to those without ET -experienced increases of 2.5% and 3.3% in DFS and 1.9% and 4.3% in RFS after 5 and 7 years of follow-up, respectively, with little difference in OS. In Cox regression analysis, no ET was significantly associated with decreased DFS (hazard ratio, HR = 1.275, p = 0.047, 95% CI[1.003-1.620]) but not OS or RFS in all patients, while in 2363 patients with pT1ab ER-positive grade 2-3 BC, no ET was significantly associated with decreased DFS (HR = 1.502, p = 0.049, 95% CI[1.001-2.252]), but not OS (HR = 1.361, p = 0.272). ET omission was not significantly associated with decreased survival in 3047 patients with pT1a-b ER-positive grade 1 BC. Conclusion: Our results indicate that while ET provided a beneficial impact on survival to patients with pT1a-bN0 ER-positive BC-and especially in those with grade 2-3 tumours-no such impact was observed in grade 1 tumours. Consequently, ET should be discussed with these patients, particularly in those with pT1a grade 1 tumours. 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Suggestions

Du même auteur

Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact

Archive ouverte | Houvenaeghel, Gilles | CCSD

International audience. BACKGROUND:Tumour features associated with isolated invasive breast cancer (BC) ipsilateral local recurrence (ILR) after breast conservative treatment (BCT) and consequences on overall surviv...

Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit

Archive ouverte | de Nonneville, Alexandre | CCSD

International audience. BACKGROUND:Invasive lobular carcinomas (ILCs) represent approximately 10% of all breast cancers. Despite this high frequency, benefit of adjuvant chemotherapy (CT) is still unclear.METHODS:Ou...

Lymph node positivity in different early breast carcinoma phenotypes: a predictive model

Archive ouverte | Houvenaeghel, Gilles | CCSD

International audience. A strong correlation between breast cancer (BC) molecular subtypes and axillary status has been shown. It would be useful to predict the probability of lymph node (LN) positivity.To develop t...

Chargement des enrichissements...